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Abstract
Introduction: In this study, we compared insulin-like growth
factor (IGF)-gene expression patterns and characteristics of
glucose and insulin metabolism in human placenta from
pregnancies with or without intrauterine growth restriction
(IUGR).
Materials and methods: We compared 101 human placentas
from intrauterine growth restriction pregnancies to those of
140 normal pregnancies treated at our department in a one-
year period. We have also assessed the serum glucose and
insulin levels of the IUGR and control groups. Several pos-
sible predicting factors of IUGR were also investigated.
Results: Risk for IUGR was suggested by gestational weight
gain and gestational increase in maternal body mass index
(BMI) as well as maternal birthweight. In pregnancies with-
out IUGR, umbilical cord glucose and insulin levels were
significantly higher than in pregnancies with IUGR. In pla-
centas from pregnancies with IUGR an overexpression of the
IGF-2 and the insulin-like growth factor binding protein
(IGFBP)-3 genes was found. In placentas from pregnancies
with male fetal gender we found a significant overexpression
of the IGF-2 gene.
Discussion: Gestational weight gain and BMI increase seem
to predict the development of IUGR. Insulin and carbohy-
drate metabolism are also impaired in IUGR fetuses. In the
placentas from pregnancies with IUGR, IGF-2 is overex-
pressed reflecting its physiological role in optimizing energy
distribution in a low-energy environment.
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Introduction
The blood flow through the uterine arteries increases signif-
icantly during a physiological pregnancy. In the first trimes-
ter it is at 50–90 mL/min, while at the end of the gestation
reaches 600–700 mL/min. This increase is due to the
decrease of the vascular resistance of both uterine arteries,
which is the consequence of the trophoblast invasion in the
spiral arteries. With normal placentation, placental circula-
tion will be physiological and the blood supply will be suit-
able for a normal intrauterine development. If the
placentation is pathological, the circulation of the placenta
will be pathological too, and a restricted fetal growth will
occur. Due to the persistent pathological circulation of the
placenta, the compensatory mechanisms of the fetus run out,
and hypoglycemia, acidosis and oliguria develop w8, 12x.
Intrauterine growth restriction (IUGR) is defined as fetal
birthweight at or below the 10th percentile for sex and ges-
tational age w40x. IUGR may result from placental dysfunc-
tion, fetal malformation, intrauterine infection or maternal
factors. The most common etiology for IUGR is thought to
be placental dysfunction, though its molecular level pathol-
ogy remains largely unknown w12, 33x. At the same time it
has to be noted, that abnormal changes in the placental bed
may occur also without IUGR, for example, in case of pre-
eclampsia.
Glucose is the single most important energy source for
intrauterine fetal growth. As fetal gluconeogenesis is mini-
mal, the bulk of glucose is provided through transplacental
glucose transport w22, 23x. Fetal hypoglycemia is very com-
mon in IUGR. The main etiology of fetal hypoglycemia is
impaired transplacental glucose transport w6x. Magnusson
and coworkers showed in 2004 that the principal mechanism
of impaired carbohydrate metabolism in IUGR is abnormal
glycolysis rather than an increased glucose demand in the
placenta w22x.
Intrauterine growth retardation is also associated with low
insulin secretion during the pregnancy, and probably a
reduced development of insuline receptors. In fetal hypoin-
sulinism there is a B cell hypotrophy, with consequences
regarding developmental programming, such as insulin resis-
tance w36x.
It has been previously hypothesized that fetal malnutrition
and the changes in the IGF axis may strongly influence and
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‘‘program’’ the fetus for future pathology w29x. Both insulin
and the growth factors IGF-1 and IGF-2 seem to be impor-
tant in the pathogenesis of IUGR. Several studies tested
umbilical cord blood levels of insulin and IGF in intrauterine
growth restriction. The majority of these studies found a
decreased level for both insulin and IGF w7, 11, 32x, while
others showed opposite results w38x.
B lymphocytes are increased in women with IUGR in
comparison with normal pregnancies and there is a signifi-
cant negative correlation between maternal B-lymphocytes
and birthweight w2x.
IGF-1 is a protein with a rather complex function. The
IGF-1 gene is located in chromosome 12 (12q22-24.1) It can
be detected in fetal tissues from the 9th gestational week and
it appears in the fetal circulation six weeks later w1, 39x. IGF-
1 receptors can be identified in the early phases of pregnancy.
During early fetal development, IGF-1 receptors show an
enhanced sensitivity to IGF-1 compared to postnatal life
w13x. Availability of IGF-1 for the fetus is regulated by six
different insulin-like growth factor binding proteins (IGFBP
1–6). In the last trimester, just as during childhood and later
life IGFBP-3 appears to be the main IGF-1 binding protein.
Together with growth hormone (GH) IGF-1 also regulates
childhood and adolescent growth.
IGF-2 is also involved in the regulation of intrauterine
growth. Its gene is located in chromosome 11 (11p15.5) in
close proximity to the insulin (INS) and thysorine-hydroxi-
lase (TH) genes. The main action of IGF-2 is mediated
through endocrine and autocrine stimulation of cellular dif-
ferentiation w16, 30x. In the first trimester, IGF-2 is mainly
produced by the fetal lungs. In the second trimester, its con-
centration in the amniotic fluid is about 3.2 times higher than
that of IGF-1 w18x.
In this study, we assessed IGF-gene expression patterns
and characteristics of insulin and carbohydrate metabolism
in placentas from IUGR pregnancies. We tried to find con-
nection between the occurrence of IUGR and the maternal
age, as well as to clear the eventual possibilities of predicting
IUGR based on clinical information. We attempted to exam-
ine the association between the serum glucose and insulin
levels, and the development of IUGR. Lastly our main aim
was to compare the placental gene expression profiles of the
IGFs and IGFBP-3 in normal and IUGR pregnancies, as well
as in male and female fetuses. We also investigated the even-
tual connection between the patterns of gene expression of
the IGF system and the severity of IUGR.
Material and methods
Patient population
We examined placentas from 101 pregnancies with intrauterine
growth restriction treated at the Semmelweis University, Second
Department of Gynecology and Obstetrics between 1 January, 2010
and 1 January, 2011 (The selection for IUGR was based on birth-
weight data in our department.). We compared placental gene
expression patterns of IGF-1, IGF-2 and IGFBP-3 as well as the
clinical characteristics (fetal gender; maternal median age; gesta-
tional weight gain of the pregnant woman; gestational body mass
index (BMI) increase of the pregnant woman; maternal birthweight)
in the IUGR group to controls gained from 140 pregnancies without
IUGR treated at our clinic in the same time period. (In certain cases
the maternal birthweight was known by verbal informations.) Where
no diagnosis of IUGR was made on the basis of standard definition,
i.e., birthweight at or below the 10th percentile for sex and gesta-
tional age. (However, in diagnosing IUGR fetal abdominal circum-
ference (AC) was also strongly considered as previously described
w20x.) In the control group the selection criteria was the birthweight
above the 10th percentile for sex and gestational age, as well as the
absence of any obstetric and genetic pathologies. Only those pla-
centas were included in the study where IUGR was likely to be due
to placental dysfunction after the exclusion of intrauterine infec-
tions, chromosomal abnormalities, developmental disorders, mater-
nal malnutrition, multiple pregnancy and structural abnormalities in
the placenta w25x. Placental dysfunction sometimes reflects abnor-
mal placental anatomy (e.g., battledore placenta, velamentous inser-
tion of the cord, single umbilical artery), it more frequently reflects
abnormal function of a normal placenta (e.g., due to smoking,
diminished perfusion, infection, infarction, chronic idiopathic villi-
tis, etc.). In some cases abnormal placental function may be due to
abnormal platelet-vessel or platelet-platelet interactions caused by
insufficient production of prostacyclin, resulting in a strong vaso-
constriction w37x.
Delivery was either vaginal or by cesarean section based on the
clinical situation. In the final analysis, no distinction was made with
respect to the type of delivery.
Placental tissue samples were taken in a uniform manner (imme-
diately after the detachment of the placenta with a sterile scalpel,
always close to the origin of the umbilical cord) with approximate
dimensions of 2 cm=2 cm=2 cm (8 cm3), which were then kept at
–708C for genetic expression testing. Maternal demographics and
relevant clinical data during pregnancy or the perinatal period were
collected including maternal and paternal age, obstetric history,
genetic history, general medical history, maternal birthweight, ges-
tational age, fetal gender, weight gain and BMI increase during
pregnancy, pregnancy-related pathology including disorders of car-
bohydrate metabolism, neonatal weight and Apgar score. Consent
was obtained in each case from the mother (signatures on file).
Umbilical cord blood sampling
In 27 pregnancies with IUGR and 32 pregnancies without, 10 mL
blood samples were obtained from the umbilical cord to test glucose
and insulin levels. Blood sampling was performed right after the
delivery, before the detachment of the placenta with sterile equip-
ment. Though the needle punction have not made the accurate local-
ization of the sampling (artery or vein) possible, we have definitely
endeavored to avoid contamination by maternal blood. Shortly after
sampling, blood samples were spun at 1800 rpm at the location of
subsequent genetic testing. Samples were kept at –708C for subse-
quent analysis. Glucose concentration was determined by Pureauto
S GLU reagent with Hitachi 7600 glucose analyzer. Insulin levels
were tested with Coat-A-Coat insulin kit.
RNA isolation and cDNA synthesis
Whole placental RNA content was isolated with Quick RNA micro-
prep kit (Zymo Research, Irvine, CA, USA). RNA concentration
was determined using NanoDrop spectophotometer (NanoDrop,
Wilmington, DE, USA). Reverse transcription was performed in
20 mL target volume using 5 mg whole RNS, 75 pmol random
hexamer primer, 10 mm dNTP (Invitrogen, Carlsbad, CA, USA), 20
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Table 1 Sequence of genes and primers used in the real-time PCR assay.
Gene and accession number Forward primer Reverse primer
IGF-1 (NC_000012) 59-AATAGAGACGGGTTTTACC-39 59-TGAGGAGAATGATCATGT-39
IGF-2 (NC_000011) 59-AGCAGGTGTGTAAACAGAGG-39 59-AGAGGTCCCACAGAGCTT-39
IGFBP3 (NC_000007) 59-TTCTGTTTGTGGTGAACTGA-39 59-GATAGGAAGCGACAAGAAAA-39
b-Actin (M10277) 59-GGCACCCAGCACAATGAAG-39 59-GCCGATCCACACGGAGTACT-39
Um-MuLV Reverse Transciptase enzyme (MBI Fermentas, Glen
Burnie, MD, USA) and 1x-es buffer (MBI Fermentas). The reaction
mix was incubated for 2 h at 428C. Subsequently, the enzyme was
inactivated at 708C for 15 min.
Real-time PCR assay
The reverse transcriptase reaction solution was diluted 3-fold with
nuclease-free water. For the real-time PCR assay, 1 mL diluted
cDNS (approximately 15 ng RNA-equivalent) and 1 x SYBR Green
Master Mixet (Applied Biosystems, Carlsbad, CA, USA) were used.
Primers were designed using Primer Express Software (Applied
Biosystems). Primer sequences are detailed in Table 1. Real-time
PCR was performed in 20 mL target volume using 1 mL cDNA,
1 pmol, gene-specific Forward and Reverse primer and 1= SYBR
Green PCR Master mix. All real-time PCR were performed using
the MX3000 Real-time PCR (Stratagen, Santa Clara, CA, USA)
system with the following settings: 40 cycles at 958C, denaturing
process for 15 s, annealing at 608C, chain elongation and detection
for 60 s. The sequence of genes and primers used in the real time
PCR is summarized in Table 1. For each gene, relative expression
was normalized using the human b-actin gene as standard.
Statistical analysis
For gene expression studies two-sample t-test was used with 95%
confidence interval. Determination of degree of freedom was per-
formed using the Welch-Satterthwaite correction. Values of gene
expression testing were interpreted in the following manner: (1)
overexpressionsLn value )1, P-0.05; (2) underexpressionsLn
value -–1, P-0.05; (3) normal expressionsLn value -1, )–1,
P-0.05. GraphPad Prism 3.0 (GraphPad Software Inc., La Jolla,
CA, USA) software was used in all statistical analytic procedures.
Demographics and clinical data were analyzed with SPSS soft-
ware. Logistic regression was used for dichotomous outcomes with
multiple independent variables. For continuous outcomes, analysis
of variance (ANOVA) and linear regression were used as appropri-
ate. P-value of -0.05 was accepted for statistical significance.
Results
Clinical data
In the IUGR group (ns101), fetal gender distribution was
37 male and 64 female (male to female ratio 0.58). In the
normal pregnancy group, male to female ratio was 1.09 (73
males, and 67 females).
The median birthweight of newborns from IUGR preg-
nancies was 2315"320 g, while 2930"280 g in the control
group.
The median value of the gestational age at delivery was
36.1"2.39 weeks in the IUGR cases and 38.3"1.79 weeks
in the control group.
In the IUGR group, median maternal age was
30.82"4.34, not statistically different from the normal preg-
nancy group (31.45"3.12, P)0.05). Analyzing IUGR out-
comes by maternal age groups, we found a statistically
significant difference (Cramer V: 0.23) with IUGR being
more common in age groups 17–24 and 35–44 when com-
pared to age groups 25–31 and 32–34 (Table 2).
Concerning the initial bodyweight of patients with IUGR
pregnancy and normal pregnancy, no significant difference
was confirmed (IUGR group: 65.9 kg; control group:
62.6 kg; P)0.05). When comparing the initial BMI values
no significant differences were found (IUGR group: 24.8;
control group: 23.8; P)0.05).
As it can be seen in Tables 3 and 4, there was a significant
difference between the groups of normal and IUGR preg-
nancies, concerning the gestational weight gain and the ges-
tational increase of BMI. In the IUGR group, mean
gestational weight gain was 10.9 kg, while in the control
group it was 14.8 kg. Similarly, in the IUGR group BMI
increased by 4.1 compared to an increase of 5.3 in the control
group. When gestational weight gain was either lower
(3–9 kg) or higher (14–17 kg) than average, a more severe
form of IUGR (birthweight 0–5 percentile) was more likely
than the ‘‘mild form’’ (birthweight 5–10 percentile), com-
pared to subjects with average gestational weight gain
(10–13 kg), associated typically with a less severe IUGR
(Cramer V: 0.35) (Table 5).
As far as maternal birthweight, those mothers who deliv-
ered babies with birthweight between 0 and 5 percentile
themselves had been born with a median birthweight of
2830 g, a birthweight significantly lower than that of mothers
who delivered babies with birthweight between 5 and 10
percentile. Median maternal birthweight in the latter group
of mothers was 3120 g.
Umbilical cord blood tests
In the IUGR group, both glucose and insulin levels were
significantly lower than in the control group (Table 6).
Gene expression studies
We had a total of 241 placenta samples available for genetic
studies; of these 101 were from pregnancies with IUGR and
140 from normal pregnancies. Gene expressions of IGF-1,
IGF-2 and IGFBP-3 were then compared between the groups
(Table 7). In the IUGR group, both IGF-2 and IGFBB-3 were
overexpressed compared to the normal pregnancy group
(IGF-2: 1.67-fold expression, Ps0.04, IGFBP-3: 1.55-fold
expression, Ps0.03).
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Table 2 Distribution of maternal age in the IUGR and normal pregnancy groups.
Maternal age (years)
17–24 25–31 32–34 35–44 Total
Normal pregnancy n 24 50 42 24 140
% 48.0% 66.6% 68.9% 43.6% 58.1%
IUGR pregnancy n 26 25 19 31 101
% 52.0% 33.3% 31.1% 56.4% 41.9%
Total n 50 75 61 55 241
Table 3 Logistic regression with gestational weight gain and ges-
tational BMI change as independent variables and IUGR or normal
pregnancy as possible outcomes. This table shows, that there was a
significant difference between the groups of normal and IUGR preg-
nancies concerning the gestational weight gain and gestational
increase of body mass index (BMI). In the IUGR group, mean ges-
tational weight gain was 10.9 kg, while in the control group it was
14.8 kg (see Table 4).
Logistic regression B Exp(B) P-value
Gestational weight gain –0.783 0.457 0.001
Gestational change in BMI 0.017 1.017 0.008
Constant 1.333 3.794 0.027
Table 4 Gestational weight gain and gestational BMI change in
the IUGR and normal pregnancy groups (gestational weight gain
and BMI change was not known in all cases).
Gestational weight BMI change
gain (kg)
Median n Median n
Normal pregnancy 14.7900 135 5.3100 133
IUGR pregnancy 10.9000 95 4.1100 74
Total 13.2000 230 4.8900 207
There was no evidence for gender difference in either IGF-
1 or IGFBP-3 gene expression as opposed to the IGF-2 gene,
where an 1.02-fold (Ps0.03) overexpression was found
(Table 8).
Within the IUGR group, there was no difference in IGF-
1, IGF-2 or IGFBP-3 gene function between those with a
more severe degree of IUGR (birthweight 0–5 percentile) vs.
those with the less severe form (birthweight 5–10 percentile)
(Table 9).
Discussion
In this study we found that in pregnancies with IUGR, male
to female ratio was significantly lower than in the control
group, which appeared to conform to the general population.
Overall, there was no difference between the groups in
terms of maternal median age. However, when maternal age
groups were considered it became evident that in the age
groups 17–24 and 35–44 IUGR was more common than in
the other groups (age groups 25–31 and 32–34; Cramer V:
0.23). It appears that in younger mothers and in those who
are somewhat older from the obstetric-genetic viewpoint
physiological growth during pregnancy may not be optimal.
This phenomenon parallels the well-known fact that in
younger and older mothers (over age 35) several obstetric
disorders are more common including premature birth, fetal
chromosomal abnormalities and IUGR itself w4, 10x. How-
ever, it must be concluded that maternal age has no signifi-
cant role in the gene expression patterns of IGF-1, IGF-2
and IGFBP-3.
In regards to the initial body weight and BMI, no signif-
icant difference was verified, though patients with IUGR
pregnancy were a bit heavier, with slightly higher initial BMI
values.
There was a significant difference between the groups both
in gestational weight gain and gestational increase of BMI.
Lower than average gestational weight gain (12.5–13 kg)
w15x appeared to predict a higher risk for IUGR.
When we stratified pregnancies by gestational weight gain
we found that in the groups where gestational weight gain
was either low (3–9 kg) or higher than average (14–17 kg)
a more severe degree of IUGR with birthweights between 0
and 5 percentile was more common than in the 10–13 kg
group. This points to the possibility that disorders that com-
monly lead to increased gestational weight gain, such as
impaired carbohydrate metabolism may have a role in the
pathogenesis of IUGR.
Mothers that gave birth to babies with birthweight
between 0 and 5 percentile had had a significantly lower
birthweight themselves raising the possibility that genetic
factors as well as developmental programming may influence
the risk for IUGR.
Postnatal umbilical cord blood studies revealed that in the
IUGR group both glucose and insulin levels were lower than
in the control group. This supports similar results of prior
studies w7, 19, 21x.
Several nutritional, hormonal and placental factors may
influence intrauterine growth. Glucose being the chief energy
source for physiological fetal growth, hypoglycemia and
hyperinsulinemia can lead to IUGR both in humans and in
several other mammalian species w28x. Fetal hypoinsulinemia
is especially important in the development of impaired bone
and soft tissue growth and leads to the proportional form of
IUGR w6–8, 20x.
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Table 5 Distribution of gestational weight gain in the group of pregnancies with more severe (neonatal birthweight 0–5 percentile) and
less severe (neonatal birthweight 5–10 percentile) form of IUGR.
Degree of IUGR by Gestational weight gain (kg) Total
gestational weight gain 3–9 10–13 14–17 )18
Neonatal weight 0–5 n 13 8 12 1 34
percentile % 46.4% 28.6% 63.2% 9.1%
5–10 n 15 20 7 10 52
% 53.6% 71.4% 36.8% 90.9%
Table 6 Glucose and insulin levels in umbilical chord blood in neonates with IUGR or normal pregnancy.
Newborns with IUGR (ns27) Normal newborns (ns32) P-value
Glucose concentration (mg/dL) 24.2"12.6 41.3"10.6 0.01
Insulin-concentration (ng/mL) 2.4"0.8 4.9"3.0 0.01
Table 7 Placental gene expression patterns of IGF-1, IGF-2 and IGFBP-3 in the IUGR group vs. normal pregnancy group as control.
Name of gene DCtnormal"SEa DCtIUGR"SEb a value"SE(a)c Ln 2a LCL UCL P-value Gene expression
IGF-1 3.18"0.82 3.10"0.7 0.08"0.5 0.05 –1.36 3.95 0.16 No change
IGF-2 4.56"0.93 2.14"0.48 2.42"0.57 1.67 0.64 3.77 0.04 Up-regulated
IGFBP-3 4.82"0.76 2.57"0.64 2.25"0.43 1.55 0.21 4.02 0.03 Up-regulated
aDCtnormalsCttested gene–Ctb-actin, bDCtIUGRsCttested gene–Ctb-actin, casDCtnormal–DCtIUGR; UCLsupper confidence limit; LCLslower confi-
dence limit; nnormals140; nIUGRs101 (P-0.05; significant).
Table 9 Placental gene expression patterns of IGF-1, IGF-2 and IGFBP-3 in the more severe form of IUGR (neonatal birthweight 0–5
percentile) vs. less severe form (neonatal birthweight 5–10 percentile) as control.
Name of gene DCtA"SEa DCtB"SEb a value"SE(a)c Ln 2a P-value Gene expression
IGF-1 3.2"0.72 2.98"0.5 0.22"0.39 0.15 0.08 No change
IGF-2 1.95"0.4 2.35"0.6 –0.4"0.42 –0.27 0.05 No change
IGFBP-3 2.8"0.81 2.3"0.47 0.5"0.6 0.34 0.04 No change
aPlacental sample from pregnancies with neonatal birth weight 5–10 percentile. bPlacental sample from pregnancies with neonatal birthweight
0–5 percentile; DCtAsCttested gene–Ctb-actin, DCtBsCttested gene–Ctb-actin, casDCtA–DCtB; nAs54; nBs38 (P-0.05; significant).
Table 8 Placental gene expression patterns of IGF-1, IGF-2 and IGFBP-3 in the male IUGR fetus vs. female IUGR fetus as control.
Name of gene DCtfemale"SEa DCtmale"SEb a value"SE(a)c Ln 2a LCL UCL P-value Gene expression
IGF-1 3.36"0.33 2.84"0.50 0.52"0.41 0.36 –0.74 0.82 0.06 No change
IGF-2 2.88"0.60 1.40"0.35 1.48"0.70 1.02 0.85 1.45 0.03 Up-regulated
IGFBP-3 3.12"0.93 2.02"0.68 1.10"0.71 0.76 –0.17 1.27 0.05 No change
aDCtfemalesCttested gene–Ctb-actin, bDCtmalesCttested gene–Ctb-actin, casDCtfemale–DCtmale; UCLsupper confidence limit; LCLslower confidence
limit; nfemales64; nmales37 (P-0.05; significant).
In our genetic expression assays, we found a significant
difference between the groups in the expression patterns of
IGF-2 and IGFBP-3 though not in IGF-1. In the former two,
significant overexpression was found. The overexpression of
the placental IGF-2 gene was previously shown in some
studies w20, 33x, though not confirmed in others w34x. One
of the most significant papers, discussing the role of IGF-2
in the placental and fetal growth, suggests that the gene of
IGF-2 control both the placental supply and the genetic
demand for maternal nutrients w3x. These data confirm our
results that IGF-2 gene overexpression may play a role in
the pathophysiology of IUGR.
Insulin-like growth factors influence both metabolic and
non-metabolic components of intrauterine growth. While
IGF-1 primarily affects nutritional intake, the main role of
IGF-2 appears to be mediated through its general regulating
effects on cellular growth and tissue-specific cell prolifera-
tion w9x. It is possible that the overexpression of the IGF-2
gene may have the function to ascertain optimal, prioritized
distribution of energy to the tissues in a low-energy environ-
706 Bo¨rzso¨nyi et al., Placental IGF expression in IUGR
Article in press - uncorrected proof
ment. This effect appears analogous to the redistribution
mechanism observed in intrauterine asphyxia w14x. The
thrifty phenotype hypothesis states that this energy redistri-
bution in IUGR comes at a price: it predicts an increased
risk for diabetes and cardiovascular problems in later post-
natal life w14, 31x.
Availability of IGF-1 and IGF-2 is regulated by six dif-
ferent binding proteins. Among these, the role of IGFBP-1
is known and discussed in the literature w17x, while that of
IGFBP-3 is less significantly expressed in papers dealing
with the connection of IGF system and IUGR, and the results
are quite inconsistent. In contrast to our findings, prior stud-
ies showed overexpression of the IGFBP-1 rather than the
IGFBP-3 gene in the IUGR placenta. Meio et al. and other
papers concluded from their examinations that newborns
with IUGR have significantly reduced IGFBP-3 levels at
birth, which suggests, that its gene is underexpressed w5, 11,
24x. At the same time Murisier-Petetin et al. and Tisi et al.
verified a high amniotic fluid concentration of IGFBP-3 in
the second trimester from pregnancies with IUGR w26, 35x.
Anyway our results based on a numerous sample confirms,
that IGFBP-3 gene overexpression plays an important role
in the pathophysiology of IUGR. It was previously supposed,
that IGFBP-3 may potentiate IGF action, and is associated
to the changes in the insulin and carbohydrate metabolism.
IGFBP-3 has both inhibitory and stimulatory effects in cell
systems, and modulates growth. IGFBP-3 also works as res-
ervoir of IGF-1, carrying it to target cells w24x. It has been
verified that IGFBP-3 increases the bioeffectiveness of IGF-
1 by 2- to 4-fold. As IGF-1 primarily affects nutritional
intake, its effectivity in the function can be positively influ-
enced by IGFBP-3, which may explain the placental overex-
pression of the IGFBP-3 gene.
In the IUGR group, the IGF-2 gene was overexpressed in
the placenta from pregnancies with male fetal gender. There
was no such gender difference in the function of either the
IGF-1 or the IGFBP-3 genes. This fetal gender-specific over-
expression of the IGF-2 gene was previously observed in the
amniotic fluid of normal pregnancies w27x. This may reflect
a possible physiological role of IGF-2 in the development of
gender-specific phenotype.
There seemed to be no relationship between the severity
of IUGR and expression patterns of the tested genes. It
appears that the severity of IUGR is therefore not primarily
linked to the IGF system. Other genetic and constitutional
factors may play a more predominant role in this regard.
In summary, we found that intrauterine growth restriction
is more common with maternal age around 20 or above 35.
Risk for IUGR is predicted by gestational weight gain and
gestational increase in maternal BMI as well as maternal
birthweight. In intrauterine growth restriction, glucose and
insulin levels are significantly lower in the umbilical cord
blood than in normal pregnancy. In human placenta from
pregnancies with IUGR the placental IGF-2 and IGFBP-3
genes are significantly overexpressed compared to placental
IGF-2 and IGFBP-3 from normal pregnancies. Based on
these an eventual connection may be supposed between the
development of chronic diseases in the adulthood and the
risk of developing IUGR. In intrauterine growth restriction,
the placental IGF-2 gene is overexpressed in the male fetus
reflecting the role of IGF-2 in the development of gender-
specific phenotype. In our study, we could not detect a rela-
tionship between the severity of IUGR and patterns of gene
expression of the IGF system.
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